Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 9—September 2012
CME ACTIVITY - Research

Effectiveness and Timing of Vaccination during School Measles Outbreak

Axel Antonio Bonačić MarinovićComments to Author , Corien Swaan, Ole Wichmann, Jim van Steenbergen, and Mirjam Kretzschmar
Author affiliations: National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands (A.A. Bonačić Marinović, C. Swaan, J. van Steenbergen, M. Kretzschmar); University Medical Centre Utrecht, Utrecht, the Netherlands (A.A. Bonačić Marinović, M. Kretzschmar); Robert Koch Institute, Berlin, Germany (O. Wichmann); and Leiden University Medical Centre, Leiden, the Netherlands (J. van Steenbergen)

Main Article

Table

Definitions of measles outbreak model parameters with assumed values and probability distribution*

Model parameter Notation Value/distribution Reference
Duration of incubation period (from distribution) Dinc Log normal (2.3,0.2); 7–14 d after infection, mode 10 d. (21–23)
Duration of latent period (distribution) Dlat (Dinc − 4) + normal (0.7); latent period ends ≈4 d before symptom onset. (21–23)
Duration of infectious period (from distribution) Dinf (Dinc + 4 − Dlat) + normal (0.7); infectious period ends ≈4 d after symptom onset. (21–23)
Duration of symptomatic period (from distribution) Dsymp Dlat + Dinf − Dinc; assumes that symptomatic period ends at same time as infectious period. (21–23)
Duration of period to build up immunity after vaccination (from distribution) Dimm 13.2 + normal (3.0); approximates measles-specific IgM positivity rates of 2% and 61% after 1 and 2 weeks of vaccination, respectively. (24)
Number of daily contacts per person (from distribution) ncont 20 + NegBin (0.155,2.2). (25)
Infection probability of a susceptible person after contact with an infectious person Pinf 0.12 in the R0≈16 scenario; 0.2348 in the R0≈31 scenario. This article (Model Calibration)
Vaccination effectiveness VES 0.9975. (5)
Infection probability of a vaccinated person after contact with an infectious person Pinf,vac Pinf (1 − VES ); 3 × 10–4 in the R0≈16 scenario; 5.869 × 10–4 in the R0≈31 scenario. This article (Vaccination)

*NegBin, negative binomial probability distribution; R0≈16, scenario in which basic reproduction number R0≈16 is considered; R0≈31, scenario in which basic reproduction number R0≈31 is considered.

Main Article

References
  1. Anderson  RM, May  RM. Vaccination and herd immunity to infectious diseases. Nature. 1985;318:323–9. DOIPubMedGoogle Scholar
  2. Anderson  RM, May  RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991. p. 70.
  3. Mossong  J, Muller  CP. Estimation of the basic reproduction number of measles during an outbreak in a partially vaccinated population. Epidemiol Infect. 2000;124:273–8. DOIPubMedGoogle Scholar
  4. Wallinga  J, Lévy-Bruhl  D, Gay  NJ, Wachmann  CH. Estimation of measles reproduction ratios and prospects for elimination of measles by vaccination in some western European countries. Epidemiol Infect. 2001;127:281–95. DOIPubMedGoogle Scholar
  5. van Boven  M, Kretzschmar  M, Wallinga  J, O’Neill  PD, Wichmann  O, Hahné  S. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. J R Soc Interface. 2010;7:1537–44. DOIPubMedGoogle Scholar
  6. van den Ent  MM, Brown  DW, Hoekstra  EJ, Christie  A, Cochi  SL. Measles mortality reduction contributes substantially to reduction of all cause mortality among children less than five years of age, 1990–2008. J Infect Dis. 2011;204(Suppl 1):S18–23. DOIPubMedGoogle Scholar
  7. World Health Organization. Weekly Epidemiological Record. 2002 Feb 15; 77, 7 [cited 2012 Apr 23]. http://www.who.int/wer/2002/wer7707/en/index.html
  8. European Center for Disease Prevention and Control. European monthly measles monitoring, March 2012. Surveillance reports; 2012 Mar 19 [cited 2010 Apr 23]. http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=843&MasterPage=1
  9. Steffens  I, Martin  R, Lopalco  P. Spotlight on measles 2010: measles elimination in Europe—a new commitment to meet the goal by 2015. Euro Surveill. 2010;15:50. DOIPubMedGoogle Scholar
  10. Aylward  RB, Clements  J, Olivé  JM. The impact of immunization control activities on measles outbreaks in middle and low income countries. Int J Epidemiol. 1997;26:662–9. DOIPubMedGoogle Scholar
  11. Grenfell  BT, Bjørnstad  ON, Kappey  J. Travelling waves and spatial hierarchies in measles epidemics. Nature. 2001;414:716–23. DOIPubMedGoogle Scholar
  12. Strebel  PM, Cochi  SL. Waving goodbye to measles. Nature. 2001;414:695–6. DOIPubMedGoogle Scholar
  13. Broutin  H, Mantilla-Beniers  NB, Simondon  F, Aaby  P, Grenfell  BT, Guégan  J-F, Epidemiological impact of vaccination on the dynamics of two childhood diseases in rural Senegal. Microbes Infect. 2005;7:593–9. DOIPubMedGoogle Scholar
  14. Grais  RF, DE Radiguès X, Dubray C, Fermon F, Guerin PJ. Exploring the time to intervene with a reactive mass vaccination campaign in measles epidemics. Epidemiol Infect. 2006;134:845–9. DOIPubMedGoogle Scholar
  15. Grais  RF, Ferrari  MJ, Dubray  C, Bjørnstad  ON, Grenfell  BT, Djibo  A, Estimating transmission intensity for a measles epidemic in Niamey, Niger: lessons for intervention. Trans R Soc Trop Med Hyg. 2006;100:867–73. DOIPubMedGoogle Scholar
  16. Grais  RF, Conlan  AJK, Ferrari  MJ, Djibo  A, Le Menach  A, Bjørnstad  ON, Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger. J R Soc Interface. 2008;5:67–74. DOIPubMedGoogle Scholar
  17. Alberti  KP, King  LA, Burny  M-E, Ilunga  BK, Grais  RF. Reactive vaccination as an effective tool for measles outbreak control in measles mortality reduction settings, Democratic Republic of Congo, 2005–2006. In Health. 2010;2:65–8. DOIGoogle Scholar
  18. World Health Organizaion. Response to measles outbreaks in measles mortality reduction settings. Immunization, Vaccines and Biologicals; 2009 [cited 2012 Apr 23]. http://www.who.int/immunization/documents/diseases/measles_who_ivb_09_03/en/index.html
  19. Wichmann  O, Siedler  A, Sagebiel  D, Hellenbrand  W, Santibanez  S, Mankertz  A, Further efforts needed to achieve measles elimination in Germany: results of an outbreak investigation. Bull World Health Organ. 2009;87:108–15. DOIPubMedGoogle Scholar
  20. Bätzing-Feigenbaum  J, Pruckner  U, Beyer  A, Sinn  G, Dinter  A, Mankertz  A, Spotlight on measles 2010: preliminary report of an ongoing measles outbreak in a subpopulation with low vaccination coverage in Berlin, Germany, January–March 2010. Euro Surveill. 2010;15:13:pii:19527.
  21. Richardson  M, Elliman  D, Maguire  H, Simpson  J, Nicoll  A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J. 2001;20:380–91. DOIPubMedGoogle Scholar
  22. Heymann  DL. Control of communicable diseases manual. Washington (DC): American Public Health Association; 2008. p. 349.
  23. LCI Measles, October 2010. In: Steenbergen JE van, Timen A, Beaujean DJMA, editor. LCI-guidelines infectious disease control edition 2011. Bilthoven (the Netherlands): LCI, Coordinator Infectious Disease Netherlands, 2011. P. 382–392.
  24. Helfand  RF, Kebede  S, Gary  HE Jr, Beyene  H, Bellini  WJ. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Clin Diagn Lab Immunol. 1999;6:178–80.PubMedGoogle Scholar
  25. Mikolajczyk  RT, Akmatov  MK, Rastin  S, Kretzschmar  M. Social contacts of school children and the transmission of respiratory-spread pathogens. Epidemiol Infect. 2008;136:813–22. DOIPubMedGoogle Scholar
  26. Uzicanin  A, Zimmerman  L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis. 2011;204(Suppl 1):S133–48. DOIPubMedGoogle Scholar
  27. Wichmann  O, Hellenbrand  W, Sagebiel  D, Santibanez  S, Ahlemeyer  G, Vogt  G, Large measles outbreak at a German public school, 2006. Pediatr Infect Dis J. 2007;26:782–6. DOIPubMedGoogle Scholar
  28. Bailey NTJ. The total size of a general stochastic epidemic. Biometrika. 1953;40:177–185. doi: http://dx.doi.org/10.1093/biomet/40.1-2.177
  29. Lloyd-Smith  JO, Schreiber  SJ, Kopp  PE, Getz  WM. Superspreading and the effect of individual variation on disease emergence. Nature. 2005;438:355–9. DOIPubMedGoogle Scholar
  30. Sakuta  H, Sawada  S, Kuroki  Y. Severity of measles among patients with incidental postexposure vaccination. Jpn J Infect Dis. 2008;61:304–6.PubMedGoogle Scholar
  31. Schmid  D, Holzmann  H, Schwarz  K, Kasper  S, Kuo  H-W, Aberle  SW, Measles outbreak linked to a minority group in Austria, 2008. Epidemiol Infect. 2010;138:415–25. DOIPubMedGoogle Scholar
  32. Wadl  M, Siedler  A, Krämer  W, Haindl  ME, Gebrande  S, Krenn-Lanzl  I, Measles transmission from an anthroposophic community to the general population, Germany 2008. BMC Public Health. 2011;11:474. DOIPubMedGoogle Scholar

Main Article

Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external